Table 4.
The clinical outcome of different total Gn dosage groups with AMH stratification
| AMH levels | Total Gn dosage (IU) | P value | ||||
|---|---|---|---|---|---|---|
| < 1875 (A) | 1875–3750 (B) | ≥ 3750 (C) | PAB | PAC | PBC | |
| The implantation rate (%) | ||||||
| Age < 35 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 41.25 (217/526) | 38.67 (198/512) | – | – | 0.410 |
| 1 < AMH ≤ 3 ng/ml | 53.74 (503/936) | 47.66 (1629/3418) | 37.55 (190/506) | 0.001 | < 0.001 | < 0.001 |
| 3 < AMH ≤ 5 ng/ml | 55.87 (856/1532) | 50.94 (708/1390) | 42.59 (23/54) | 0.008 | 0.069 | 0.267 |
| AMH > 5 ng/ml | 58.43 (582/996) | 51.65 (219/424) | 0 | 0.019 | – | – |
| Age 35–42 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 27.86 (73/262) | 23.01 (127/552) | – | – | 0.139 |
| 1 < AMH ≤ 3 ng/ml | 38.68 (41/106) | 30.07 (329/1094) | 24.81 (133/536) | 0.078 | 0.004 | 0.030 |
| 3 < AMH ≤ 5 ng/ml | 34.66 (61/176) | 30.75 (115/374) | 21.05 (8/38) | 0.379 | 0.127 | 0.266 |
| AMH > 5 ng/ml | 47.22 (34/72) | 36.11 (26/72) | 0 | 0.237 | – | – |
| The clinical pregnancy rate (%) | ||||||
| Age < 35 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 61.98 (163/263) | 57.42 (147/256) | – | – | 0.325 |
| 1 < AMH ≤ 3 ng/ml | 76.50 (358/468) | 69.87 (1194/1709) | 60.87 (154/253) | 0.006 | < 0.001 | 0.005 |
| 3 < AMH ≤ 5 ng/ml | 77.15 (591/766) | 70.94 (493/695) | 62.96 (17/27) | 0.007 | 0.104 | 0.392 |
| AMH > 5 ng/ml | 79.12 (394/498) | 72.64 (154/212) | 0 | 0.064 | – | – |
| Age 35–42 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 45.04 (59/131) | 38.77 (107/276) | – | – | 0.237 |
| 1 < AMH ≤ 3 ng/ml | 58.49 (31/53) | 47.90 (262/547) | 41.42 (111/268) | 0.152 | 0.024 | 0.086 |
| 3 < AMH ≤ 5 ng/ml | 59.09 (52/88) | 49.73 (93/187) | 36.84 (7/19) | 0.156 | 0.126 | 0.340 |
| AMH > 5 ng/ml | 66.67 (24/36) | 63.89 (23/36) | 0 | 1.000 | – | – |
| The live birth rate (%) | ||||||
| Age < 35 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 47.53 (125/263) | 44.14 (113/256) | – | – | 0.481 |
| 1 < AMH ≤ 3 ng/ml | 58.12 (272/468) | 56.35 (963/1709) | 50.59 (128/253) | 0.494 | 0.059 | 0.090 |
| 3 < AMH ≤ 5 ng/ml | 63.32 (485/766) | 57.55 (400/695) | 48.15 (13/27) | 0.028 | 0.155 | 0.428 |
| AMH > 5 ng/ml | 64.86 (323/498) | 60.85 (129/212) | 0 | 0.348 | – | – |
| Age 35–42 Y | ||||||
| AMH ≤ 1 ng/ml | 0 | 29.77 (39/131) | 26.81 (74/276) | – | – | 0.555 |
| 1 < AMH ≤ 3 ng/ml | 45.28 (24/53) | 30.90 (169/547) | 27.99 (75/268) | 0.044 | 0.015 | 0.416 |
| 3 < AMH ≤ 5 ng/ml | 40.91 (36/88) | 32.62 (61/187) | 21.05 (4/19) | 0.223 | 0.123 | 0.438 |
| AMH > 5 ng/ml | 52.78 (19/36) | 38.89 (14/36) | 0 | 0.344 | – | – |
The IVF-ET cycles of 2 embryos at the cleavage stage with endometrial thickness ≥ 7 mm on ET day were included. PAB: < 1875 IU group vs. 1875–3750 IU group. PAC: < 1875 IU group vs. ≥ 3750 IU group. PBC: 1875–3750 IU group vs. ≥ 3750 IU group. AMH anti-Müllerian hormone, Gn gonadotropin. P < 0.05 was considered statistically significant. -, not applicable